{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T05:18:27Z","timestamp":1765603107401,"version":"3.48.0"},"reference-count":39,"publisher":"MDPI AG","issue":"24","license":[{"start":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T00:00:00Z","timestamp":1765411200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Eisai Co., Ltd."}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: We investigated the role of pharmacists in adverse event (AE) management during renal cell carcinoma (RCC) drug therapy by surveying patients, physicians, and pharmacists. We identified the types of AEs for which pharmacist involvement is beneficial and explored measures to promote pharmacist intervention. Methods: This was an ad hoc analysis of a questionnaire-based cross-sectional web survey conducted from May to June 2022 among patients undergoing RCC drug therapy, physicians prescribing RCC treatments, and pharmacists involved in oncology care in Japan. Results: A total of 83 patients with metastatic RCC, 165 physicians, and 218 pharmacists were included. Among patients, 28.9% reported experiencing AEs or symptoms requiring pharmacist intervention. Most physicians (78.2%) and pharmacists (96.3%) supported pharmacist involvement in AE management. Notably, 35.6% of patients who reported no AEs or symptoms requiring pharmacist intervention acknowledged difficulty in communicating AEs to their physicians. Regarding desired pharmacist interventions for AEs, patients prioritized rash\/pruritus, fatigue, and diarrhea; physicians emphasized stomatitis and anorexia; pharmacists identified constipation, stomatitis, and diarrhea. The most common reason patients valued pharmacist involvement was the reassurance of support from multiple healthcare providers. Physicians and pharmacists valued pharmacists\u2019 greater familiarity with AE management, particularly considering physicians\u2019 limited time. Raising awareness among patients and healthcare professionals, patient requests, and improving institutional support were strategies to enhance pharmacist involvement. Over 86% of healthcare professionals considered pharmaceutical outpatient clinics necessary to strengthen interdisciplinary collaboration. Conclusions: This study highlights widespread support among patients, physicians, and pharmacists for pharmacist involvement in managing AEs during RCC drug therapy.<\/jats:p>","DOI":"10.3390\/cancers17243951","type":"journal-article","created":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T08:39:18Z","timestamp":1765442358000},"page":"3951","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Perceptions and Expectations of Pharmacist Interventions in Adverse Event Management During Drug Therapy for Metastatic Renal Cell Carcinoma: A Cross-Sectional Survey in Japan"],"prefix":"10.3390","volume":"17","author":[{"given":"Tetsuya","family":"Wako","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Nippon Medical School Musashikosugi Hospital, Kawasaki 211-8533, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0088-9324","authenticated-orcid":false,"given":"Go","family":"Kimura","sequence":"additional","affiliation":[{"name":"Department of Urology, Nippon Medical School Hospital, Tokyo 113-8603, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhisa","family":"Fujii","sequence":"additional","affiliation":[{"name":"Department of Urology, Institute of Science Tokyo, Tokyo 113-8510, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Osawa","sequence":"additional","affiliation":[{"name":"Department of Urology, Hokkaido University Hospital, Sapporo 060-8638, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yosuke","family":"Uchitomi","sequence":"additional","affiliation":[{"name":"Department of Cancer Survivorship and Digital Medicine, The Jikei University School of Medicine, Tokyo 105-8461, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5090-9771","authenticated-orcid":false,"given":"Kazunori","family":"Honda","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, Aichi Cancer Center, Nagoya 464-8681, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miki","family":"Kondo","sequence":"additional","affiliation":[{"name":"Department of Nursing, National Cancer Center Hospital East, Kashiwa 277-8577, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ariko","family":"Otani","sequence":"additional","affiliation":[{"name":"Department of Nursing, National Cancer Center Hospital East, Kashiwa 277-8577, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihide","family":"Mitsuda","sequence":"additional","affiliation":[{"name":"Eisai Co., Ltd., Tokyo 112-8088, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuo","family":"Shinohara","sequence":"additional","affiliation":[{"name":"Department of Urology, Kushiro Rosai Hospital, Kushiro 085-0052, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,12,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1056\/NEJMra1601333","article-title":"Systemic therapy for metastatic renal-cell carcinoma","volume":"376","author":"Choueiri","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1007\/s10147-021-01979-9","article-title":"Prognosis of Japanese metastatic renal cell carcinoma patients in the targeted therapy era","volume":"26","author":"Naito","year":"2021","journal-title":"Int. J. Clin. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e7196","DOI":"10.1002\/cam4.7196","article-title":"Cross-sectional study of therapy-related expectations\/concerns of patients with metastatic renal cell carcinoma and physicians in Japan","volume":"13","author":"Kimura","year":"2024","journal-title":"Cancer Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/s41687-022-00533-z","article-title":"Patient-reported experiences with side effects of kidney cancer therapies and corresponding information flow","volume":"6","author":"Kastrati","year":"2022","journal-title":"J. Patient Rep. Outcomes"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.urolonc.2013.09.009","article-title":"A cross-sectional investigation of fatigue in advanced renal cell carcinoma treatment: Results from the FAMOUS study","volume":"32","author":"Goebell","year":"2014","journal-title":"Urol. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1200\/EDBK_236857","article-title":"The value and future developments of multidisciplinary team cancer care","volume":"39","author":"Selby","year":"2019","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Roberto, M., Panebianco, M., Aschelter, A.M., Buccilli, D., Cantisani, C., Caponnetto, S., Cortesi, E., d\u2019Amuri, S., Fofi, C., and Ierin\u00f2, D. (2023). The value of the multidisciplinary team in metastatic renal cell carcinoma: Paving the way for precision medicine in toxicities management. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.1026978"},{"key":"ref_8","first-page":"73","article-title":"From oncology pharmacy to pharmaceutical care: New contributions to multidisciplinary cancer care","volume":"12","author":"Liekweg","year":"2004","journal-title":"Support. Care Cancer"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1177\/10781552241263997","article-title":"Trend analysis of pharmacist involvement in cancer care in Japan from 2015 to 2020: A nationwide survey study on hospital pharmacy practice","volume":"31","author":"Tsuchiya","year":"2025","journal-title":"J. Oncol. Pharm. Pract."},{"key":"ref_10","first-page":"5043","article-title":"Management of adverse events in patients with metastatic renal cell carcinoma treated with sunitinib and clinical outcomes","volume":"33","author":"Yoshizawa","year":"2013","journal-title":"Anticancer Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s40780-014-0005-0","article-title":"Effectiveness of medical supportive team for outpatients treated with sorafenib: A retrospective study","volume":"1","author":"Kajizono","year":"2015","journal-title":"J. Pharm. Health Care Sci."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1177\/1078155219897129","article-title":"Evaluation of pharmacist interventions in a head and neck medical oncology clinic","volume":"26","author":"Lau","year":"2020","journal-title":"J. Oncol. Pharm. Pract."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1177\/1078155218817937","article-title":"Expansion of pharmacist clinical services to optimize the management of immune checkpoint inhibitor toxicities","volume":"25","author":"Renna","year":"2019","journal-title":"J. Oncol. Pharm. Pract."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1177\/1078155219861679","article-title":"Drug-related problems with targeted\/immunotherapies at an oncology outpatient clinic","volume":"26","author":"Kucuk","year":"2020","journal-title":"J. Oncol. Pharm. Pract."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1177\/1078155220928407","article-title":"Impact of pharmacist-managed immune checkpoint inhibitor toxicities","volume":"27","author":"Le","year":"2021","journal-title":"J. Oncol. Pharm. Pract."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Kimura, G., Fujii, Y., Honda, K., Osawa, T., Uchitomi, Y., Kondo, M., Otani, A., Wako, T., Kawai, D., and Mitsuda, Y. (2024). Financial toxicity in Japanese patients with metastatic renal cell carcinoma: A cross-sectional study. Cancers, 16.","DOI":"10.3390\/cancers16101904"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Shawahna, R., and Awawdeh, H. (2021). Pharmacists\u2019 knowledge, attitudes, beliefs, and barriers toward breast cancer health promotion: A cross-sectional study in the Palestinian territories. BMC Health Serv. Res., 21.","DOI":"10.1186\/s12913-021-06458-5"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"4427","DOI":"10.7314\/APJCP.2012.13.9.4427","article-title":"Knowledge, perception, practice and barriers of breast cancer health promotion activities among community pharmacists in two Districts of Selangor state, Malaysia","volume":"13","author":"Beshir","year":"2012","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"ref_19","first-page":"25","article-title":"Barriers to effective pharmacy practice in low- and middle-income countries","volume":"3","author":"Babar","year":"2014","journal-title":"Integr. Pharm. Res. Pract."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Horio, F., Ikeda, T., Kouzaki, Y., Hirahara, T., Masa, K., Narita, S., Tomita, Y., Tsuruzoe, S., Fujisawa, A., and Akinaga, Y. (2023). Questionnaire survey on pharmacists\u2019 roles among non- and health care professionals in medium-sized cities in Japan. Sci. Rep., 13.","DOI":"10.1038\/s41598-023-32777-0"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"23743735231211883","DOI":"10.1177\/23743735231211883","article-title":"Public\u2019s perception of pharmacist","volume":"10","year":"2023","journal-title":"J. Patient Exp."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"iv111","DOI":"10.1093\/annonc\/mdy148","article-title":"Diagnosis, assessment and management of constipation in advanced cancer: ESMO Clinical Practice Guidelines","volume":"29","author":"Larkin","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1200\/JOP.19.00652","article-title":"Management of cancer therapy-associated oral mucositis","volume":"16","author":"Brown","year":"2020","journal-title":"JCO Oncol. Pract."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e447","DOI":"10.1016\/S1470-2045(14)70006-3","article-title":"Guidance on the management of diarrhoea during cancer chemotherapy","volume":"15","author":"Andreyev","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_25","first-page":"280","article-title":"2020 ASCO, 2023 NCCN, 2023 MASCC\/ESMO, and 2019 CCO: A comparison of antiemetic guidelines for the treatment of chemotherapy-induced nausea and vomiting in cancer patients","volume":"32","author":"Kennedy","year":"2024","journal-title":"Support. Care Cancer"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.2147\/CMAR.S417238","article-title":"The incidence and management of cancer-related anorexia during treatment with vascular endothelial growth factor receptor-tyrosine kinase inhibitors","volume":"15","author":"Takahashi","year":"2023","journal-title":"Cancer Manag. Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1001\/jamaoncol.2016.6914","article-title":"Comparison of pharmaceutical, psychological, and exercise treatments for cancer-related fatigue: A meta-analysis","volume":"3","author":"Mustian","year":"2017","journal-title":"JAMA Oncol."},{"key":"ref_28","first-page":"1081","article-title":"A systematic review of dysgeusia induced by cancer therapies","volume":"18","author":"Hovan","year":"2010","journal-title":"Support. Care Cancer"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1200\/JCO.2011.39.7372","article-title":"Evidence-based treatment of depression in patients with cancer","volume":"30","author":"Li","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1002\/pon.1945","article-title":"Usefulness of pharmacist-assisted screening and psychiatric referral program for outpatients with cancer undergoing chemotherapy","volume":"20","author":"Ito","year":"2011","journal-title":"Psychooncology"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s40780-018-0105-3","article-title":"Impact of pharmacist counseling on reducing instances of adverse events that can affect the quality of life of chemotherapy outpatients with breast Cancer","volume":"4","author":"Tanaka","year":"2018","journal-title":"J. Pharm. Health Care Sci."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"999","DOI":"10.21873\/anticanres.13205","article-title":"Usefulness of implementing comprehensive pharmaceutical care for metastatic renal cell carcinoma outpatients treated with pazopanib","volume":"39","author":"Todo","year":"2019","journal-title":"Anticancer Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1177\/10781552211061133","article-title":"Evaluation and clinical impact of a pharmacist-led, interdisciplinary service focusing on education, monitoring and toxicity management of immune checkpoint inhibitors","volume":"29","author":"Myers","year":"2023","journal-title":"J. Oncol. Pharm. Pract."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1007\/s13187-022-02196-2","article-title":"Cross-sectional census survey of patients with cancer who received a pharmacist consultation in a pharmacist led anti-cancer clinic","volume":"37","author":"Dennis","year":"2022","journal-title":"J. Cancer. Educ."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"e47","DOI":"10.3802\/jgo.2025.36.e47","article-title":"Shared decision-making in patients with gynecological cancer and healthcare professionals: A cross-sectional observational study in Japan","volume":"36","author":"Abe","year":"2025","journal-title":"J. Gynecol. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1177\/1078155218798138","article-title":"Impact of pharmacy collaborating services in an outpatient clinic on improving adverse drug reactions in outpatient cancer chemotherapy","volume":"25","author":"Suzuki","year":"2019","journal-title":"J. Oncol. Pharm. Pract."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1111\/j.1365-2753.2011.01665.x","article-title":"Pharmacists contribute to the improved efficiency of medical practices in the outpatient cancer chemotherapy clinic","volume":"18","author":"Iihara","year":"2012","journal-title":"J. Eval. Clin. Pract."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1177\/1078155218783814","article-title":"A systematic review of the impact of outpatient clinical pharmacy services on medication-related outcomes in patients receiving anticancer therapies","volume":"25","author":"Maleki","year":"2019","journal-title":"J. Oncol. Pharm. Pract."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"20677","DOI":"10.1002\/cam4.6591","article-title":"The efficacy of molecular targeted therapy and nivolumab therapy for metastatic non-clear cell renal cell carcinoma: A retrospective analysis using the Michinoku Japan urological cancer study group database","volume":"12","author":"Koguchi","year":"2023","journal-title":"Cancer Med."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/24\/3951\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T05:16:50Z","timestamp":1765603010000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/24\/3951"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,11]]},"references-count":39,"journal-issue":{"issue":"24","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["cancers17243951"],"URL":"https:\/\/doi.org\/10.3390\/cancers17243951","relation":{},"ISSN":["2072-6694"],"issn-type":[{"type":"electronic","value":"2072-6694"}],"subject":[],"published":{"date-parts":[[2025,12,11]]}}}